FBInvestor
Stocks / An2 Therapeutics Inc
Institutional Ownership

An2 Therapeutics Inc

CUSIP 037326105COMANTXQ1 2026

13D / 13G Filings
41
Schedule 13D/13G on record
Beneficial Filers
19
Distinct reporting persons
Largest Stake
19.6%
Max % of class reported
Institutional Holders
49
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

41 filings · latest Mar 13, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Mar 13, 2026Vivo Opportunity Fund Holdings, L.P.13G8.0%2.86MSEC
2Mar 13, 2026Integrated Core Strategies (Us) LLC13G6.3%2.24MSEC
3Feb 17, 2026Almitas Capital LLC13G5.4%2.98MSEC
4Feb 13, 2026Eric Easom13G/A7.9%2.23MSEC
5Nov 14, 2025Almitas Capital LLC13G11.0%1.43MSEC
6Jun 18, 2025Bml Investment Partners, L.P.13D/A1.4%SEC
7Jun 4, 2025Coastlands Capital LP13G9.3%SEC
8May 30, 2025Bml Investment Partners, L.P.13D/A10.7%SEC
9May 7, 2025Bml Investment Partners, L.P.13D19.1%SEC
10Feb 28, 2025Adjuvant Global Health Technology Fund, L.P.13G/A7.9%2.37MSEC

31 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for An2 Therapeutics Inc.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →